DCAT Report: 2026 CDMO Market Sees Major M&A and Capital Investments, with Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion

DCAT Value Chain Insights USA

Overview

According to a DCAT Value Chain Insights report, the 2026 CDMO market is witnessing a surge in peptide-based drug development, accompanied by significant M&A and capital investments. Samsung Biologics plans to acquire peptide API specialist PolyPeptide Group for $1.8 billion, expanding its capabilities beyond antibodies and ADCs. Concurrently, major Western CDMOs like BSP Pharmaceuticals (200 million euros) and Vetter Pharma International (approximately 480 million euros) are announcing substantial manufacturing capacity enhancements.

In Depth

Key Findings

A report from DCAT Value Chain Insights highlights that the Contract Development and Manufacturing Organization (CDMO) market in 2026 is characterized by a continued surge in peptide-based drug development, accompanied by significant mergers and acquisitions (M&A) and substantial investments in manufacturing capacity. Notably, Samsung Biologics’ planned acquisition of PolyPeptide Group, a specialist in peptide active pharmaceutical ingredients (APIs), for $1.8 billion, marks a major strategic realignment within the CDMO industry.

Technical/Clinical Details

Key developments in the CDMO sector for 2026 include:

• Samsung Biologics Acquires PolyPeptide Group ($1.8 billion): In a strategic move to expand its API manufacturing capabilities beyond monoclonal antibodies and antibody-drug conjugates (ADCs), Samsung Biologics is set to acquire PolyPeptide Group, a leading peptide CDMO, for $1.8 billion. This acquisition will solidify Samsung Biologics’ position as an integrated CDMO capable of supporting a wider array of therapeutic modalities.
• BSP Pharmaceuticals Expands Manufacturing Capacity (€200 million): Italy-based BSP Pharmaceuticals is investing €200 million to enhance its manufacturing capacity. This strategic move aims to meet the increasing demand for oncology and other highly potent pharmaceutical manufacturing.
• Vetter Pharma International Builds New Facility (approx. €480 million): Germany’s Vetter Pharma International is constructing a new facility with an investment of approximately €480 million to strengthen its aseptic fill-and-finish services. This addresses the global demand for advanced drug delivery systems and sterile manufacturing of biologics.
• Evonik Boosts API Manufacturing Capacity ($100 million in the US): Evonik is investing $100 million at its Tippecanoe Labs site in Indiana, USA, to enhance its API manufacturing capabilities, specifically targeting the growing demand for complex high-potency APIs (HPAPIs).
• Grand River Aseptic Manufacturing (GRAM) Increases Sterile Injectable Capacity ($100 million): US-based GRAM is investing $100 million to expand its sterile injectable manufacturing capacity. This initiative is aimed at accelerating the market entry of biologics and complex sterile formulations.

Background & Context

The CDMO market continues its rapid growth, driven by the increasing complexity of biopharmaceutical development, the emergence of diverse therapeutic modalities, and the deepening outsourcing strategies of pharmaceutical companies. Peptide-based drugs, with their therapeutic potential and relatively shorter development timelines, have gained significant attention recently. These acquisitions and large-scale capital investments clearly indicate CDMOs’ efforts to capture demand in this growing market and establish a competitive advantage. The ability to cater to novel modalities such as mRNA, cell and gene therapies, ADCs, and radiopharmaceuticals is becoming a key differentiator for CDMOs.

Strategic Significance & Outlook

These major investments and strategic maneuvers within the CDMO industry are expected to continue. Samsung Biologics’ acquisition of PolyPeptide Group signifies the emergence of a new mega-CDMO in the peptide drug sector, potentially reshaping the industry landscape. Capacity expansions by leading European and American CDMOs will contribute to strengthening global supply chains and accelerating innovation. This will enable pharmaceutical companies to develop and manufacture new drugs more efficiently and rapidly, ultimately leading to greater patient access to innovative therapies.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime